Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...
The National Multiple Sclerosis Society has committed $18.1 million in multi-year funding to support research projects aligned with its Pathways to Cures roadmap that focuses on three critical areas: ...
Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...
HOUSTON, Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development ...
Challenges remain, like regulatory hurdles and funding, but our team's grit and your support as shareholders make me ...
Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...
The Marburg variant of multiple sclerosis is extremely rare but also the most severe. Life expectancy has been weeks or months, but advances in treatment have led to an improved outlook. Multiple ...
Maggie Aime has over 25 years of experience in healthcare and as a nurse across specialties including oncology, kidney transplant, cardiology, and more. She leverages her rich healthcare experience to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback